期刊
CURRENT OPINION IN PHARMACOLOGY
卷 62, 期 -, 页码 64-73出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2021.11.006
关键词
-
This article discusses the clinical trials and mutations during the COVID-19 pandemic, identifying potential therapeutic candidates and explaining the impact of mutations in S-glycoprotein and RdRp on therapeutic drugs and antibodies.
Several clinical trials started during the COVID-19 pandemic to discover effective therapeutics led to identify a few candidates from the major clinical trials. However, in the past several months, quite a few SARS-CoV-2 variants have emerged with significant mutations. Major mutations in the S-glycoprotein and other parts of the genome have led to the antibody's escape to small molecule-based therapeutic resistance. The mutations in S-glycoprotein trigger the antibody escape/resistance, and mutations in RdRp might cause remdesivir resistance. The article illustrates emerging mutations that have resulted in antibody escape to therapeutics resistance. In this direction, the article illustrates presently developed neutralizing antibodies (with their preclinical, clinical stages) and antibody escapes and associated mutations. Finally, owing to the RdRp mutations, the antiviral small molecules resistance is illustrated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据